Fruquintinib Plus Irinotecan in the Treatment of Advanced Gastric Cancer
Status:
Not yet recruiting
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
This study explores the efficacy and safety of fruquintinib combined with irinotecan in the
second-line treatment of patients with advanced gastric cancer, aiming to bring more
second-line treatment options for patients with advanced gastric cancer.